Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

14.89
-0.3500-2.30%
Post-market: 14.79-0.1000-0.67%18:17 EDT
Volume:955.99K
Turnover:14.31M
Market Cap:2.60B
PE:-5.25
High:15.36
Open:15.26
Low:14.81
Close:15.24
52wk High:34.47
52wk Low:12.72
Shares:174.32M
Float Shares:66.98M
Volume Ratio:0.76
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8352
EPS(LYR):-2.7303
ROE:-77.58%
ROA:-47.07%
PB:4.27
PE(LYR):-5.45

Loading ...

BRIEF-Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications

Reuters
·
Apr 21

Immunovant CEO Salzmann Retires; Roivant Exec Venker Takes the Helm

Dow Jones
·
Apr 21

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

GlobeNewswire
·
Apr 21

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?

Insider Monkey
·
Apr 08

Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?

Insider Monkey
·
Mar 26

BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate

Reuters
·
Mar 21

Buy Rating Affirmed for IMVT-1402: Promising Study Results and Strategic Focus in FcRn Space

TIPRANKS
·
Mar 21

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Zacks
·
Mar 20

Immunovant Is Maintained at Buy by B of A Securities

Dow Jones
·
Mar 20

Immunovant price target lowered to $33 from $38 at BofA

TIPRANKS
·
Mar 20

Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 20

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Benzinga
·
Mar 20

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright

TIPRANKS
·
Mar 20

Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG

TIPRANKS
·
Mar 19

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Reuters
·
Mar 19

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

Blockhead
·
Mar 05

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Mar 03

Jefferies Initiates Immunovant at Hold With $20 Price Target

MT Newswires Live
·
Mar 03

Immunovant initiated with a Hold at Jefferies

TIPRANKS
·
Mar 03

Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
Feb 24